Samjin Pharm (005500) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Samjin Pharm KRW 22,008, price KRW 18,450, upside +19.3%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Samjin Pharm for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 15,569 KRW – 24,700 KRW · fair‑value band 13,119 KRW – 32,230 KRW · the 18,450 KRW price screens below the 22,008 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Samjin Pharm in your weekly email
Every Wednesday you see whether Samjin Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms.
Show more
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Stock analysis
Samjin Pharm (005500) currently trades at 18,450 KRW, while our model-based Fair Value estimate is 22,008 KRW, implying the stock looks roughly 16.2% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 34,456 KRW per share, and 15 of the 23 models we run sit above the 18,450 KRW price.
Bear case: the Growth DCF group reads lowest at 8,873 KRW, and 8 of the 23 models stay below the price. Evidence for this calculation is medium.
Scenario range: 13,119 KRW (bear) to 32,230 KRW (bull), the price of 18,450 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Samjin Pharm reported revenue of 309B KRW in FY2025 versus 250B KRW in FY2021, a compound +5.4%/yr. Reported net income was 24.2B KRW in FY2025, compounding −4.0%/yr from FY2021.
Key figures
Market cap 226B KRW (≈ $166M) · P/S ratio 0.89 · Dividend yield 4.3% · Net margin 7.8% · Return on equity 20.3% · Return on assets (EBIT) 6.8% · Operating margin 22.6% · Revenue (TTM) 254B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 19%, 005500 screens cheaper than that median.
Fair Value models
Bear 13,119 KRWFair Value 22,008 KRWBull 32,230 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +3.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.7%
Dividend (yield on the price)4.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +23.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside+19% · Above median
Profitability
Return on equity (TTM)20% · Top 25%
Return on assets13% · Top 25%
Net margin (TTM)16% · Top 25%
Operating margin (TTM)23% · Top 25%
Growth and dividend
Revenue growth2% · Below median
Dividend yield (TTM)4.3% · Top 25%
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Samjin Pharm Fair Value". https://www.fairvalue-calculator.com/stock/005500
Frequently asked questions
Is Samjin Pharm (005500) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 22,008 KRW versus a price of 18,450 KRW, about +19% upside (undervalued).
What is the fair value of 005500?
Our model-based fair value for Samjin Pharm is 22,008 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 18,450 KRW.
What is the quality score of 005500?
Samjin Pharm has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Samjin Pharm (005500)?
Our model-based price target is the fair value of 22,008 KRW (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 13,119 KRW, optimistic scenario 32,230 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Samjin Pharm stock forecast for 2026?
Our models put fair value at 22,008 KRW, about +19% upside versus a price of 18,450 KRW (undervalued). Cautious scenario 13,119 KRW, optimistic scenario 32,230 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Samjin Pharm (005500)?
Samjin Pharm reported trailing-twelve-month revenue of about 254B KRW (latest available figure, as of Sep 24, 2026).
Does Samjin Pharm pay a dividend?
Samjin Pharm currently shows a dividend yield of about 4.34% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Samjin Pharm (005500)?
For today's price to be fair in a discounted-cash-flow model, Samjin Pharm would have to grow free cash flow by +25.9 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 005500 use?
Our models discount Samjin Pharm at 11.6 %: a base by market capitalisation (micro), damped by beta 0.06, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Samjin Pharm that is +25.9 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Samjin Pharm (005500) delivered so far?
Over the past 5 years revenue at Samjin Pharm grew +5.6 % a year. The price currently implies +25.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Samjin Pharm (005500) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Samjin Pharm (+25.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Samjin Pharm (005500)?
The free-cash-flow yield on the price is 4.25 %: that much free cash flow Samjin Pharm produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Samjin Pharm (005500)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Samjin Pharm it is 22,008 KRW per share (as of Sep 24, 2026), against a price of 18,450 KRW. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Samjin Pharm stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 005500 trades below its calculated fair value: price 18,450 KRW, fair value 22,008 KRW, a gap of about +19% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 005500?
No. The price is what the market pays today (18,450 KRW); the fair value is what the company's own numbers justify (22,008 KRW). For Samjin Pharm the two are 3,558 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Samjin Pharm worth?
The market values Samjin Pharm at about 226B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 18,450 KRW; our models calculate a fair value of 22,008 KRW per share.
What do the bullish and bearish scenarios say about 005500?
Our models span a range for Samjin Pharm: cautious scenario 13,119 KRW, base 22,008 KRW, optimistic 32,230 KRW per share (as of Sep 24, 2026, price 18,450 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Samjin Pharm (005500)?
Balance-sheet figures for Samjin Pharm (as of Sep 24, 2026): return on equity 20.3%, debt of 0.10 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 005500 from its 52-week high?
Samjin Pharm trades at 18,450 KRW, about 25% below its 52-week high of 24,700 KRW and 8% above the low of 17,060 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 22,008 KRW is for.
Which stocks are comparable to Samjin Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Samjin Pharm stock attractive at the current price?
The data as of Sep 24, 2026: price 18,450 KRW, calculated fair value 22,008 KRW (+19%), Quality Score 58/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 005500 calculated?
We run Samjin Pharm through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 22,008 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Samjin Pharm currently trades 19 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Samjin Pharm (005500)?
The closing price on Sep 23, 2026 was 18,450 KRW. Our model-based fair value is 22,008 KRW, about +19% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Samjin Pharm right now?
A fairly wide model range (13,119 KRW to 32,230 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Samjin Pharm
How large is the market capitalisation of Samjin Pharm (005500)?
The market capitalisation of Samjin Pharm is 226B KRW (≈ $166M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Samjin Pharm (005500)?
The price-to-sales ratio of Samjin Pharm is 0.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Samjin Pharm (005500)?
The dividend yield of Samjin Pharm is 4.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Samjin Pharm (005500)?
The net margin of Samjin Pharm is 7.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Samjin Pharm (005500)?
The return on equity (ROE) of Samjin Pharm is 20.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Samjin Pharm (005500)?
On an EBIT basis the return on assets of Samjin Pharm is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Samjin Pharm (005500)?
The operating margin of Samjin Pharm is 22.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Samjin Pharm (005500)?
Revenue at Samjin Pharm is growing +1.9% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Samjin Pharm (005500)?
Earnings per share at Samjin Pharm are growing +9.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Samjin Pharm (005500) carry?
The net debt of Samjin Pharm is 122B KRW (fiscal year 2025, ≈ 12.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Samjin Pharm in the live analysis
One click puts Samjin Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
